Lamar Smith bought Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 (--)
Lamar Smith (R-TX), a U.S. Representative, has disclosed 90 trades in Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 (--) since 2013, 45 purchases and 45 sales, worth an estimated $712K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Lamar Smith bought Unknown of Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 (--) on January 2, 2019. Since that trade, -- is up +0.00% against the S&P 500 up +235.02%, an outperformance of -235.02%.
Across these filings, Lamar Smith has been a balanced trader of -- (a buy-to-sell ratio of 1.00). Each row in the table below links to that trade and its post-trade performance versus the market.
Data updated
Lamar Smith's -- trades vs the price
-- is up +0.00% since Lamar Smith bought on January 2, 2019, versus +235.02% for the S&P 500.
Performance since this trade
All Lamar Smith -- trades
Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.
Lamar Smith & -- trading FAQ
Is it legal for Lamar Smith to trade Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 (--) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 (--), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; this page does not imply the trade was improper.
When did Lamar Smith buy --?
Lamar Smith disclosed a purchase of Unknown of Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 (--) on January 2, 2019, according to public STOCK Act filings.
How has -- performed since Lamar Smith's trade?
Since Lamar Smith bought -- on January 2, 2019, the stock is up +0.00%, versus +235.02% for the S&P 500 over the same period, an outperformance of -235.02%.
How many times has Lamar Smith traded --?
Lamar Smith has disclosed 90 -- trades since 2013 (45 purchases and 45 sales). Every disclosed trade is listed on this page.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional -- trades?
BullishWhales tracks every disclosed congressional trade in Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 (--) on the Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019 congressional trading page, which aggregates filings across all members of Congress.
Lamar Smith's -- tradesAll congressional filings for Portola Pharmaceuticals, Inc. (PTLa) [ST] F ILINg S TaTUS : New S UbHoLdINg o F : MERRILL LYNCH INVESTMENT aCCoUNTS eTAIlS O fferINGS AND S IGNATure Hon. Lamar Smith , 01/10/2019Lamar Smith's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.